Atomoxetine (Strattera) for ADHD
Med Lett Drugs Ther 2003 Feb 3;45(1149):11-12

ABSTRACT

Atomoxetine (Strattera) is the first non-stimulant drug to be approved by the FDA for treatment of attention deficit hyperactivity disorder (ADHD). Unlike other drugs approved for use in ADHD, it is not a controlled substance and is approved for use in adults as well as children. Older non-stimulant drugs that have been used to treat ADHD, although not FDA-approved, include the alpha2-agonist clonidine (Catapres, and others) and the tricyclic antidepressant desiprimine (Norpramin, and others) (Medical Letter 1996; 38:109). This review describes pharmacology of the atomoxetine. Published clinical trials are presented, along with a description of adverse effects, drug interactions, dosage and cost. The review also includes a comparison chart of the costs and dosages of drugs used for treatment of ADHD. The article concludes with an overall assessment of atomoxetine's safety and efficacy.

ADHD
Options
Noradrenaline
Drug companies
Tomoxetine and ADHD
Tomoxetine from Eli Lilly
Is Strattera safe for kids?
Once-daily tomoxetine for ADHD
Big Pharma meets Madison Avenue
Antidepressants to treat ADHD in adults
Tomoxetine (Strattera) v methylphenidate (Ritalin)

Refs
HOME
HedWeb
Future Opioids
BLTC Research
Paradise-Engineering
Utopian Pharmacology
The Hedonistic Imperative
When Is It Best To Take Crack Cocaine?

The Good Drug Guide
The Responsible Parent's Guide
To Healthy Mood Boosters For All The Family